Apportionment of cost of acquisition of shares post demerger: general guidance for shareholders

India Glycols has shared general guidance on splitting the original cost of acquisition of its shares after the demerger.

Tue 6 Oct 2026

Cost apportionment - India Glycols

31.77%

Cost apportionment - Ennature Bio Pharma

20.61%

Cost apportionment - IGL Spirits

47.62%

What this update is about

India Glycols has shared general guidance for shareholders on how to split the original cost of acquisition of their shares, after two undertakings were demerged into two new companies — Ennature Bio Pharma Limited (Resulting Company 1) and IGL Spirits Limited (Resulting Company 2).

The Scheme of Arrangement was sanctioned by the Hon'ble National Company Law Tribunal, Allahabad Bench, Prayagraj, by order dated 17th July, 2026, and the Scheme became effective from 1st September, 2026.

How the original cost is to be split

Shareholders may apportion the original cost of acquisition of their India Glycols equity shares as follows:

• India Glycols Limited: 31.77% of the total cost of acquisition
• Ennature Bio Pharma Limited: 20.61%
• IGL Spirits Limited: 47.62%

Put simply, this is the share of the cost you originally paid for India Glycols shares that is treated as the cost of each set of shares you now hold. The apportionment matters mainly when these shares are sold and capital gains are computed. This is the proportion of your own original cost, not a price or a value of the shares.

Shares allotted and the entitlement ratio

Equity shares of face value Rs. 5/- each of the two resulting companies were allotted to shareholders of the Demerged Company whose names appeared in the Register of Members maintained by the depositories as on the Record Date, Wednesday, 2nd September, 2026:

• 1 (One) Equity Share of Resulting Company 1 for every 3 (Three) Equity Shares held in the Demerged Company
• 1 (One) Equity Share of Resulting Company 2 for every 1 (One) Equity Share held in the Demerged Company

The demerger transferred and vested the Bio Pharma undertaking in Resulting Company 1 and the Spirits & Biofuel Undertaking(s) in Resulting Company 2, on a going concern basis.

Points to keep in mind

The communication is described as being for general guidance and not a substitute for any independent opinion shareholders may obtain. It notes that a regulatory, statutory or judicial authority, including any assessing officer or appropriate appellate authority, could take a different view, and shareholders are advised to consult their own consultants or tax advisors for their specific tax implications. The Company states it takes no express or implied responsibility or liability in relation to this guidance.

The communication is also hosted on the Company's website.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.